TacticScaleWhat Aptargroup Does & How It Makes Money (ATR)
Updated October 2026 · reflects Aptargroup's latest reported financials
Maker of dispensing, drug-delivery and packaging components for consumer brands. It sells dispensing and packaging components and related services to pharmaceutical and consumer-product companies.
How Aptargroup makes money
It sells dispensing and packaging components and related services to pharmaceutical and consumer-product companies. Sales run through three segments (Pharma, Beauty and Closures) across Asia, Europe, Latin America and North America.
What Aptargroup does
AptarGroup, Inc. makes the parts that deliver a product from its container to the user: pumps, sprays, aerosol valves and closures. Its customers are in pharmaceuticals, fragrance, skincare, color cosmetics, personal care, home care and food and beverage. It runs three segments. Pharma covers drug delivery systems, such as metered-dose valves and fine-mist pumps, plus elastomeric primary packaging, active material science and digital health solutions. Beauty covers dispensing for fragrance, skincare and cosmetics. Closures covers dispensing and non-dispensing caps for consumer goods. The company was incorporated in 1992 and is headquartered in Crystal Lake, Illinois. It sells mainly in Asia, Europe, Latin America and North America. Much of its product range goes into regulated pharmaceutical uses as well as everyday consumer goods, so its business spans both healthcare and consumer markets.
Products & services
- Fine-mist and lotion dispensing pumps
- Metered-dose and continuous spray aerosol valves
- Dispensing and non-dispensing closures
- Elastomeric primary packaging components
- Active material science solutions
- Digital health solutions
What is Aptargroup worth?
On an owner-earnings DCF, Aptargroup's most-likely value is about $104 versus a recent price near $120 (14% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$54) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Amphastar Pharmaceuticals (AMPH) · Aptiv (APTV) · Amcor (AMCR) · West Pharmaceutical Services (WST) · Avantor (AVTR)